Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam

被引：0
|
作者：
Hoang, G. H. Nguyen [1 ]
Nguyen, P. T. B. [2 ]
Nguyen, H. T. N. [2 ]
Do, K. H. [2 ]
机构：
[1] Hanoi Oncol Hosp, Med Dept 1, Hanoi, Vietnam
[2] K Hosp, Med Dept 1, Hanoi, Vietnam
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
275P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Rituximab with high-dose methotrexate in primary central nervous system lymphoma
    Kansara, Roopesh
    Shenkier, Tamara N.
    Connors, Joseph M.
    Sehn, Laurie H.
    Savage, Kerry J.
    Gerrie, Alina S.
    Villa, Diego
    AMERICAN JOURNAL OF HEMATOLOGY, 2015, 90 (12) : 1149 - 1154
  • [2] Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience
    Ly, K. Ina
    Crew, Laura L.
    Graham, Carrie A.
    Mrugala, Maciej M.
    ONCOLOGY LETTERS, 2016, 11 (05) : 3471 - 3476
  • [3] Management of Patients With Primary Central Nervous System Lymphoma Treated With High-Dose Methotrexate
    Warnick, Elizabeth
    Auger, Danielle
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2009, 13 (02) : 177 - 180
  • [4] White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab
    Fayez Estephan
    Xiaobu Ye
    Omar Dzaye
    Nina Wagner-Johnston
    Lode Swinnen
    Douglas E. Gladstone
    Rich Ambinder
    David Olayinka Kamson
    Sebastian Lambrecht
    Stuart A. Grossman
    Doris D. M. Lin
    Matthias Holdhoff
    Journal of Neuro-Oncology, 2019, 145 : 461 - 466
  • [5] White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab
    Estephan, Fayez
    Ye, Xiaobu
    Grossman, Stuart A.
    Lin, Doris D.
    Holdhoff, Matthias
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] Correction to: White matter changes in primary central nervous system lymphoma patients treated with high-dose methotrexate with or without rituximab
    Fayez Estephan
    Xiaobu Ye
    Omar Dzaye
    Nina Wagner-Johnston
    Lode Swinnen
    Douglas E. Gladstone
    Rich Ambinder
    David Olayinka Kamson
    Sebastian Lambrecht
    Stuart A. Grossman
    Doris D. M. Lin
    Matthias Holdhoff
    Journal of Neuro-Oncology, 2019, 145 : 467 - 467
  • [7] Ibrutinib in Combination with Rituximab and High-Dose Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma Patients
    Guo, Yixian
    Lan, Xiaoxi
    Chang, Xiaoli
    Wang, Guoxiang
    Zou, Dongmei
    Su, Li
    Sun, Wanling
    BLOOD, 2021, 138
  • [8] High-dose methotrexate combined with rituximab improves the survival rate of patients with primary central nervous system lymphoma
    Ma, Jing
    Ma, Xianjun
    JOURNAL OF BUON, 2021, 26 (02): : 366 - 372
  • [9] High-dose methotrexate dosing strategy in primary central nervous system lymphoma
    Wang, Alexander
    Cirrone, Frank
    De los Reyes, Francis Andrew
    Papadopoulos, John
    Saint Fleur-Lominy, Shella
    Xiang, Elaine
    LEUKEMIA & LYMPHOMA, 2022, 63 (06) : 1348 - 1355
  • [10] Hepatotoxicity from high-dose methotrexate in primary central nervous system lymphoma
    Zhang, Joy C.
    Stotts, Matthew J.
    Horton, Bethany
    Schiff, David
    NEURO-ONCOLOGY PRACTICE, 2023, 10 (03) : 291 - 300
12345